New Real-World study to test remibrutinib for chronic hives
NCT ID NCT07358364
First seen Jan 25, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study follows about 3,280 adults with chronic spontaneous urticaria (CSU) to see how well remibrutinib controls their hives in real-world settings. Participants either continue standard antihistamines or switch to remibrutinib, as decided by their doctor. The main goal is to measure symptom control and safety over 24 months. This is an observational study, meaning no new treatments are assigned—just careful tracking of outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Cleaver Dermatology
RECRUITINGKirksville, Missouri, 63501, United States
Conditions
Explore the condition pages connected to this study.